{"id":4189,"date":"2026-10-19T11:26:16","date_gmt":"2026-10-19T15:26:16","guid":{"rendered":"https:\/\/canasanta.ca\/?p=4189"},"modified":"2026-10-19T11:26:16","modified_gmt":"2026-10-19T15:26:16","slug":"merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras","status":"publish","type":"post","link":"https:\/\/canasanta.ca\/en\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/","title":{"rendered":"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras"},"content":{"rendered":"

La alemana Merck KGaA anunci\u00f3 este lunes 19 de octubre un acuerdo para adquirir Silence Therapeutics por aproximadamente 1.300 millones de d\u00f3lares, una operaci\u00f3n que incorpora a su cartera una plataforma de ARN interferente y un tratamiento experimental avanzado para la policitemia vera, un raro c\u00e1ncer de la sangre.<\/h3>\n

El acuerdo, anunciado esta ma\u00f1ana y confirmado tanto por Merck como por Silence Therapeutics, contempla el pago de 20 d\u00f3lares en efectivo por cada ADS de la biotecnol\u00f3gica brit\u00e1nica. Reuters inform\u00f3 de la operaci\u00f3n este lunes. La transacci\u00f3n todav\u00eda no est\u00e1 cerrada: requiere aprobaciones regulatorias, el respaldo de los accionistas de Silence y la autorizaci\u00f3n judicial correspondiente en Reino Unido.<\/p>\n

<\/div>\n

Una tecnolog\u00eda dise\u00f1ada para silenciar genes<\/strong><\/h2>\n

El principal atractivo cient\u00edfico de Silence Therapeutics es su plataforma de ARN peque\u00f1o interferente, conocida como siRNA. Esta tecnolog\u00eda busca bloquear de manera selectiva mensajes gen\u00e9ticos implicados en determinadas enfermedades y reducir as\u00ed la producci\u00f3n de prote\u00ednas que contribuyen al proceso patol\u00f3gico.<\/p>\n

La adquisici\u00f3n dar\u00eda a Merck acceso a divesiran, un medicamento experimental preparado para avanzar a fase 3 en pacientes con policitemia vera dependiente de flebotom\u00edas. La policitemia vera es una neoplasia mieloproliferativa cr\u00f3nica en la que la m\u00e9dula \u00f3sea produce demasiados gl\u00f3bulos rojos, aumentando el riesgo de complicaciones cardiovasculares y tromb\u00f3ticas.<\/p>\n

<\/div>\n

Divesiran apunta a reducir las extracciones de sangre<\/strong><\/h2>\n

Divesiran est\u00e1 dise\u00f1ado para silenciar TMPRSS6, un gen relacionado con la regulaci\u00f3n de la hepcidina, una hormona clave para controlar el metabolismo del hierro. Al aumentar la hepcidina, el tratamiento pretende limitar el hierro disponible para producir gl\u00f3bulos rojos y mantener bajo control el hematocrito.<\/p>\n

Seg\u00fan los resultados de fase 2 comunicados por las compa\u00f1\u00edas, el estudio SANRECO registr\u00f3 una tasa de respuesta del 88 % con divesiran frente al 19 % con placebo. El promedio de flebotom\u00edas durante las primeras 36 semanas fue de 0,2 por paciente con el tratamiento experimental frente a 2,1 con placebo. Estos datos son prometedores, pero divesiran contin\u00faa siendo un medicamento en investigaci\u00f3n y todav\u00eda debe superar ensayos confirmatorios y el proceso regulatorio antes de una eventual aprobaci\u00f3n.<\/p>\n

<\/div>\n

Una compra que todav\u00eda debe superar varias condiciones<\/strong><\/h2>\n

El precio acordado representa una valoraci\u00f3n de capital cercana a 1.300 millones de d\u00f3lares y un valor empresarial de aproximadamente 1.100 millones. Los 20 d\u00f3lares por ADS suponen una prima del 130 % sobre el cierre de Silence del 16 de octubre y del 82 % sobre su precio medio ponderado de los \u00faltimos 30 d\u00edas, seg\u00fan las compa\u00f1\u00edas.<\/p>\n

La operaci\u00f3n fue aprobada por los \u00f3rganos corporativos correspondientes, pero a\u00fan necesita el voto de los accionistas de Silence, autorizaciones regulatorias y la sanci\u00f3n del Tribunal Superior de Justicia de Inglaterra y Gales. Si se cumplen esas condiciones, las compa\u00f1\u00edas esperan cerrar la adquisici\u00f3n durante el primer trimestre de 2027.<\/p>\n

<\/div>\n

La carrera por convertir el ARN en medicamentos<\/strong><\/h2>\n

El inter\u00e9s de Merck refleja la creciente importancia de las terapias capaces de intervenir sobre mecanismos gen\u00e9ticos concretos. A diferencia de una compra puramente financiera, la operaci\u00f3n incorpora una plataforma tecnol\u00f3gica y un candidato cl\u00ednico avanzado que podr\u00eda abrir a la compa\u00f1\u00eda una nueva posici\u00f3n en hematolog\u00eda y enfermedades raras.<\/p>\n

Silence tambi\u00e9n desarrolla otros programas basados en siRNA. Sin embargo, el valor cl\u00ednico definitivo de estos tratamientos depender\u00e1 de los resultados de ensayos posteriores y de la evaluaci\u00f3n de los reguladores. Por ahora, el hecho nuevo y confirmado es el acuerdo de adquisici\u00f3n anunciado este 19 de octubre, no la aprobaci\u00f3n de un nuevo medicamento.<\/p>","protected":false},"excerpt":{"rendered":"

La alemana Merck KGaA anunci\u00f3 este lunes 19 de octubre un acuerdo para adquirir Silence Therapeutics por aproximadamente 1.300 millones de d\u00f3lares, una operaci\u00f3n que incorpora a su cartera una plataforma de ARN interferente y un tratamiento experimental avanzado para la policitemia vera, un raro c\u00e1ncer de la sangre. El acuerdo, anunciado esta ma\u00f1ana y […]<\/p>\n","protected":false},"author":284226809,"featured_media":4192,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[33205457,2127],"tags":[33207107,33207105,33207106,33207108],"class_list":["post-4189","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-al-dia","category-salud","tag-policitemia-vera","tag-silence-therapeutics","tag-sirna","tag-terapias-de-arn"],"acf":[],"yoast_head":"\nMerck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras - Ca\u00f1asanta<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/canasanta.ca\/en\/health\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras\" \/>\n<meta property=\"og:description\" content=\"La alemana Merck KGaA anunci\u00f3 este lunes 19 de octubre un acuerdo para adquirir Silence Therapeutics por aproximadamente 1.300 millones de d\u00f3lares, una operaci\u00f3n que incorpora a su cartera una plataforma de ARN interferente y un tratamiento experimental avanzado para la policitemia vera, un raro c\u00e1ncer de la sangre. El acuerdo, anunciado esta ma\u00f1ana y […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/canasanta.ca\/en\/health\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/\" \/>\n<meta property=\"og:site_name\" content=\"Ca\u00f1asanta\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-19T15:26:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?resize=1200,630&quality=85&strip=all&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ca\u00f1asanta\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ca\u00f1asanta\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/\"},\"author\":{\"name\":\"Ca\u00f1asanta\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\"},\"headline\":\"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras\",\"datePublished\":\"2026-10-19T15:26:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/\"},\"wordCount\":621,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"keywords\":[\"Policitemia vera\",\"Silence Therapeutics\",\"siRNA\",\"Terapias de ARN\"],\"articleSection\":[\"AL D\u00cdA!\",\"Salud\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/\",\"name\":\"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras - Ca\u00f1asanta\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"datePublished\":\"2026-10-19T15:26:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1\",\"width\":1200,\"height\":630,\"caption\":\"Laboratorio de investigaci\u00f3n gen\u00e9tica y secuenciaci\u00f3n, imagen editorial sobre terapias siRNA y la adquisici\u00f3n de Silence Therapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AL D\u00cdA!\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/category\\\/al-dia\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"name\":\"Ca\u00f1asanta\",\"description\":\"Magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/canasanta.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\",\"name\":\"Ca\u00f1asanta\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"width\":1500,\"height\":500,\"caption\":\"Ca\u00f1asanta\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\",\"name\":\"Ca\u00f1asanta\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"caption\":\"Ca\u00f1asanta\"},\"sameAs\":[\"http:\\\/\\\/canasantaonline-pbuqn.wordpress.com\"],\"url\":\"https:\\\/\\\/canasanta.ca\\\/en\\\/author\\\/canasantaonline\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras - Ca\u00f1asanta","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/canasanta.ca\/en\/health\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/","og_locale":"en_US","og_type":"article","og_title":"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras","og_description":"La alemana Merck KGaA anunci\u00f3 este lunes 19 de octubre un acuerdo para adquirir Silence Therapeutics por aproximadamente 1.300 millones de d\u00f3lares, una operaci\u00f3n que incorpora a su cartera una plataforma de ARN interferente y un tratamiento experimental avanzado para la policitemia vera, un raro c\u00e1ncer de la sangre. El acuerdo, anunciado esta ma\u00f1ana y […]","og_url":"https:\/\/canasanta.ca\/en\/health\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/","og_site_name":"Ca\u00f1asanta","article_published_time":"2026-10-19T15:26:16+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?resize=1200,630&quality=85&strip=all&ssl=1","type":"image\/jpeg"}],"author":"Ca\u00f1asanta","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ca\u00f1asanta","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/#article","isPartOf":{"@id":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/"},"author":{"name":"Ca\u00f1asanta","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93"},"headline":"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras","datePublished":"2026-10-19T15:26:16+00:00","mainEntityOfPage":{"@id":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/"},"wordCount":621,"commentCount":0,"publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"image":{"@id":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","keywords":["Policitemia vera","Silence Therapeutics","siRNA","Terapias de ARN"],"articleSection":["AL D\u00cdA!","Salud"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/","url":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/","name":"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras - Ca\u00f1asanta","isPartOf":{"@id":"https:\/\/canasanta.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/#primaryimage"},"image":{"@id":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","datePublished":"2026-10-19T15:26:16+00:00","breadcrumb":{"@id":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/#primaryimage","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","width":1200,"height":630,"caption":"Laboratorio de investigaci\u00f3n gen\u00e9tica y secuenciaci\u00f3n, imagen editorial sobre terapias siRNA y la adquisici\u00f3n de Silence Therapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/canasanta.ca\/salud\/merck-apuesta-1-300-millones-por-terapias-que-silencian-genes-contra-enfermedades-raras\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/canasanta.ca\/"},{"@type":"ListItem","position":2,"name":"AL D\u00cdA!","item":"https:\/\/canasanta.ca\/category\/al-dia\/"},{"@type":"ListItem","position":3,"name":"Merck apuesta $1.300 millones por terapias que silencian genes contra enfermedades raras"}]},{"@type":"WebSite","@id":"https:\/\/canasanta.ca\/#website","url":"https:\/\/canasanta.ca\/","name":"Ca\u00f1asanta","description":"Magazine","publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/canasanta.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/canasanta.ca\/#organization","name":"Ca\u00f1asanta","url":"https:\/\/canasanta.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","width":1500,"height":500,"caption":"Ca\u00f1asanta"},"image":{"@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93","name":"Ca\u00f1asanta","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","caption":"Ca\u00f1asanta"},"sameAs":["http:\/\/canasantaonline-pbuqn.wordpress.com"],"url":"https:\/\/canasanta.ca\/en\/author\/canasantaonline\/"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/phoxY0-15z","jetpack-related-posts":[{"id":5165,"url":"https:\/\/canasanta.ca\/en\/salud\/vacuna-arnm-reduce-42-riesgo-recaida-melanoma\/","url_meta":{"origin":4189,"position":0},"title":"UNA VACUNA DE ARNm REDUCE UN 42% EL RIESGO DE RECA\u00cdDA DEL MELANOMA","author":"Ca\u00f1asanta","date":"October 23, 2026","format":false,"excerpt":"Una vacuna personalizada de ARNm de Moderna y Merck, combinada con Keytruda, redujo un 42% el riesgo de reca\u00edda o muerte por melanoma en un ensayo de fase 3.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Investigaci\u00f3n de una vacuna personalizada contra el c\u00e1ncer en laboratorio","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5394,"url":"https:\/\/canasanta.ca\/en\/salud\/farmaco-oral-johnson-johnson-tumores-prostata\/","url_meta":{"origin":4189,"position":1},"title":"UN F\u00c1RMACO ORAL HACE RETROCEDER TUMORES DE PR\u00d3STATA","author":"Ca\u00f1asanta","date":"October 24, 2026","format":false,"excerpt":"Un medicamento experimental de toma diaria desarrollado por Johnson & Johnson logr\u00f3 que tumores de pr\u00f3stata desaparecieran o redujeran su tama\u00f1o en pacientes de un ensayo cl\u00ednico en fase inicial, seg\u00fan resultados divulgados este s\u00e1bado. El avance abre una nueva v\u00eda para tratar uno de los c\u00e1nceres m\u00e1s frecuentes entre\u2026","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Medicamentos orales, imagen editorial para ensayo de c\u00e1ncer de pr\u00f3stata","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Farmaco-oral-experimental-contra-cancer-de-prostata.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Farmaco-oral-experimental-contra-cancer-de-prostata.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Farmaco-oral-experimental-contra-cancer-de-prostata.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Farmaco-oral-experimental-contra-cancer-de-prostata.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Farmaco-oral-experimental-contra-cancer-de-prostata.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5580,"url":"https:\/\/canasanta.ca\/en\/salud\/nuevo-farmaco-alarga-vida-cancer-endometrio\/","url_meta":{"origin":4189,"position":2},"title":"UN NUEVO F\u00c1RMACO ALARGA LA VIDA EN C\u00c1NCER DE ENDOMETRIO","author":"Ca\u00f1asanta","date":"October 26, 2026","format":false,"excerpt":"Un f\u00e1rmaco experimental de Merck prolong\u00f3 la supervivencia en c\u00e1ncer de endometrio avanzado y recibi\u00f3 revisi\u00f3n prioritaria de la FDA.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Secci\u00f3n patol\u00f3gica de un \u00fatero con adenocarcinoma del endometrio","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Adenocarcinoma-del-endometrio-%E2%80%94-imagen-patologica.jpg?fit=1200%2C431&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Adenocarcinoma-del-endometrio-%E2%80%94-imagen-patologica.jpg?fit=1200%2C431&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Adenocarcinoma-del-endometrio-%E2%80%94-imagen-patologica.jpg?fit=1200%2C431&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Adenocarcinoma-del-endometrio-%E2%80%94-imagen-patologica.jpg?fit=1200%2C431&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Adenocarcinoma-del-endometrio-%E2%80%94-imagen-patologica.jpg?fit=1200%2C431&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4899,"url":"https:\/\/canasanta.ca\/en\/salud\/qiagen-cambia-de-manos-10800-millones\/","url_meta":{"origin":4189,"position":3},"title":"Qiagen cambia de manos por 10.800 millones de d\u00f3lares","author":"Ca\u00f1asanta","date":"October 21, 2026","format":false,"excerpt":"EQT comprar\u00e1 Qiagen por unos 10.800 millones de d\u00f3lares, una operaci\u00f3n que refuerza el valor estrat\u00e9gico del diagn\u00f3stico molecular y la medicina de precisi\u00f3n.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"T\u00e9cnico de laboratorio realizando pruebas de diagn\u00f3stico molecular","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Diagnostico-molecular-en-laboratorio-%E2%80%94-Qiagen.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Diagnostico-molecular-en-laboratorio-%E2%80%94-Qiagen.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Diagnostico-molecular-en-laboratorio-%E2%80%94-Qiagen.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Diagnostico-molecular-en-laboratorio-%E2%80%94-Qiagen.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Diagnostico-molecular-en-laboratorio-%E2%80%94-Qiagen.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":4693,"url":"https:\/\/canasanta.ca\/en\/salud\/fda-hibsago-hepatitis-b-tratamiento-2026\/","url_meta":{"origin":4189,"position":4},"title":"LA FDA ABRE UNA PUERTA CONTRA LA HEPATITIS B CR\u00d3NICA","author":"Ca\u00f1asanta","date":"October 20, 2026","format":false,"excerpt":"La FDA aprueba Hibsago, primer tratamiento antisentido contra la hepatitis B cr\u00f3nica; cerca de uno de cada cinco pacientes seleccionados mantuvo control viral tras suspender la terapia.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Investigadora trabajando con microscopio en laboratorio, imagen editorial sobre el nuevo tratamiento contra la hepatitis B","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Hepatitis-B-nuevo-tratamiento-aprobado-por-FDA.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Hepatitis-B-nuevo-tratamiento-aprobado-por-FDA.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Hepatitis-B-nuevo-tratamiento-aprobado-por-FDA.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Hepatitis-B-nuevo-tratamiento-aprobado-por-FDA.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Hepatitis-B-nuevo-tratamiento-aprobado-por-FDA.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":1866,"url":"https:\/\/canasanta.ca\/en\/al-dia\/una-nueva-arma-contra-la-diabetes\/","url_meta":{"origin":4189,"position":5},"title":"A NEW WEAPON AGAINST DIABETES","author":"Ca\u00f1asanta","date":"September 29, 2026","format":false,"excerpt":"Una nueva pastilla experimental consigui\u00f3 reducir con fuerza los niveles de az\u00facar en pacientes con diabetes tipo 2. Se llama safiglipron, se toma una vez al d\u00eda, no necesita ayuno y ya complet\u00f3 ensayos cl\u00ednicos fase 3. China estudia actualmente su autorizaci\u00f3n. La diabetes tipo 2 afecta a cientos de\u2026","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"CS diabetes new001","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/09\/CS_diabetes_new001.jpg?fit=1200%2C631&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]}],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Terapias-de-ARN-y-medicina-genetica.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1","_links":{"self":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/users\/284226809"}],"replies":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/comments?post=4189"}],"version-history":[{"count":3,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4189\/revisions"}],"predecessor-version":[{"id":4193,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/4189\/revisions\/4193"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media\/4192"}],"wp:attachment":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media?parent=4189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/categories?post=4189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/tags?post=4189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}